1
|
Mir IH, Anilkumar AS, Guha S, Mohanty AK, Suresh Kumar M, Sujatha V, Ramesh T, Thirunavukkarasu C. Elucidation of 7,8-dihydroxy flavone in complexing with the oxidative stress-inducing enzymes, its impact on radical quenching and DNA damage: an in silico and in vitro approach. J Biomol Struct Dyn 2024; 42:4048-4063. [PMID: 37261742 DOI: 10.1080/07391102.2023.2218932] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2023] [Accepted: 05/21/2023] [Indexed: 06/02/2023]
Abstract
Oxidative stress (OS) has been attributed to the progression of various disorders, including cancer, diabetes, and cardiovascular diseases. Several antioxidant compounds and free radical quenchers have been shown to mitigate oxidative stress. However, large-scale randomized controlled trials of such compounds on chronic disease aversion have yielded paradoxical and disappointing results due to the constrained cognizance of their oxidative mechanisms and therapeutic targets. The current study sought to identify the potential therapeutic targets of 7,8-Dihydroxyflavone (7,8-DHF) by analyzing its interactions with the enzymes implicated in oxidative stress and also to explore its radicle quenching potential and prophylactic impact on the H2O2-induced DNA damage. Through the in silco approach, we investigated the antioxidant potential of 7,8-DHF by evaluating its interactions with the human oxidative stress-inducing enzymes such as myeloperoxidase (MPO), NADPH oxidase (NOX), nitric oxide synthase (NOS), and xanthine oxidase (XO) and a comparative analysis of those interactions with known antioxidants (Ascorbic acid, Melatonin, Tocopherol) used as controls. The best-scoring complex was adopted for the simulation analysis in investigating protein-ligand conformational dynamics. The in vitro radicle quenching potential was evaluated by performing a spectrum of antioxidant assays, and radical quenching was observed in a dose-dependent fashion with IC50 values of < 60 µM/mL. Further, we probed its anti-hemolytic potential and prophylactic impact in avian erythrocytes subjected to H2O2-induced hemolysis and DNA damage by implementing hemolysis and comet assays. The protective effect was more pronounced at higher concentrations of the drug.Communicated by Ramaswamy H. Sarma.
Collapse
Affiliation(s)
- Ishfaq Hassan Mir
- Department of Biochemistry and Molecular Biology, Pondicherry University, Puducherry, India
| | | | - Shreyoshi Guha
- Department of Biochemistry and Molecular Biology, Pondicherry University, Puducherry, India
| | | | | | - Venugopal Sujatha
- DST-Mobility Fellow, Department of Chemistry, Pondicherry University, Puducherry, India
- Department of Chemistry, Periyar University, Salem, Tamil Nadu, India
| | - Thiyagarajan Ramesh
- Department of Basic Medical Sciences, College of Medicine, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia
| | | |
Collapse
|
2
|
Kaci H, Dombi Á, Gömbös P, Szabó A, Bakos É, Özvegy-Laczka C, Poór M. Interaction of mycotoxins zearalenone, α-zearalenol, and β-zearalenol with cytochrome P450 (CYP1A2, 2C9, 2C19, 2D6, and 3A4) enzymes and organic anion transporting polypeptides (OATP1A2, OATP1B1, OATP1B3, and OATP2B1). Toxicol In Vitro 2024; 96:105789. [PMID: 38341109 DOI: 10.1016/j.tiv.2024.105789] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2023] [Revised: 02/05/2024] [Accepted: 02/07/2024] [Indexed: 02/12/2024]
Abstract
Zearalenone (ZEN) is a mycoestrogen produced by Fusarium fungi. ZEN is a frequent contaminant in cereal-based products, representing significant health threat. The major reduced metabolites of ZEN are α-zearalenol (α-ZEL) and β-zearalenol (β-ZEL). Since the toxicokinetic interactions of ZEN/ZELs with cytochrome P450 enzymes (CYPs) and organic anion transporting polypeptides (OATPs) have been barely characterized, we examined these interactions applying in vitro models. ZEN and ZELs were relatively strong inhibitors of CYP3A4 and moderate inhibitors of CYP1A2 and CYP2C9. Both CYP1A2 and CYP3A4 decreased ZEN and β-ZEL concentrations in depletion assays, while only CYP1A2 reduced α-ZEL levels. OATPs tested were strongly or moderately inhibited by ZEN and ZELs; however, these mycotoxins did not show higher cytotoxicity in OATP-overexpressing cells. Our results help the deeper understanding of the toxicokinetic/pharmacokinetic interactions of ZEN, α-ZEL, and β-ZEL.
Collapse
Affiliation(s)
- Hana Kaci
- Drug Resistance Research Group, Institute of Enzymology, Research Centre for Natural Sciences, HUN-REN, Magyar tudósok krt. 2, Budapest H-1117, Hungary; Doctoral School of Biology, Institute of Biology, Eötvös Loránd University, Pázmány P. stny. 1/C, Budapest H-1117, Hungary
| | - Ágnes Dombi
- Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, Pécs H-7624, Hungary
| | - Patrik Gömbös
- Institute of Physiology and Nutrition, Department of Physiology and Animal Health, Agribiotechnology and Precision Breeding for Food Security National Laboratory, Hungarian University of Agriculture and Life Sciences, Gödöllő H-2103, Hungary
| | - András Szabó
- Institute of Physiology and Nutrition, Department of Physiology and Animal Health, Agribiotechnology and Precision Breeding for Food Security National Laboratory, Hungarian University of Agriculture and Life Sciences, Gödöllő H-2103, Hungary; HUN-REN-MATE Mycotoxins in the Food Chain Research Group, Hungarian University of Agriculture and Life Sciences, Guba Sándor Str. 40, Kaposvár 7400, Hungary
| | - Éva Bakos
- Drug Resistance Research Group, Institute of Enzymology, Research Centre for Natural Sciences, HUN-REN, Magyar tudósok krt. 2, Budapest H-1117, Hungary
| | - Csilla Özvegy-Laczka
- Drug Resistance Research Group, Institute of Enzymology, Research Centre for Natural Sciences, HUN-REN, Magyar tudósok krt. 2, Budapest H-1117, Hungary
| | - Miklós Poór
- Department of Laboratory Medicine, Medical School, University of Pécs, Ifjúság útja 13, Pécs H-7624, Hungary; Molecular Medicine Research Group, János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary.
| |
Collapse
|
3
|
Fliszár-Nyúl E, Ungvári O, Dombi Á, Özvegy-Laczka C, Poór M. Interactions of Mycotoxin Alternariol with Cytochrome P450 Enzymes and OATP Transporters. Metabolites 2022; 13:metabo13010045. [PMID: 36676970 PMCID: PMC9862037 DOI: 10.3390/metabo13010045] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2022] [Revised: 12/19/2022] [Accepted: 12/26/2022] [Indexed: 12/31/2022] Open
Abstract
Alternariol (AOH) is an emerging mycotoxin produced by Alternaria strains. The acute toxicity of the mycotoxin is low; however, chronic exposure to AOH may result in the development of endocrine disruptor and/or carcinogenic effects. The toxicokinetic properties of AOH have barely been characterized. Therefore, in this study, we aimed to investigate its interactions with CYP (1A2, 2C9, 2C19, 2D6, and 3A4) enzymes and OATP (1A2, 1B1, 1B3, and 2B1) transporters employing in vitro enzyme assays and OATP overexpressing cells, respectively. Our results demonstrated that AOH is a strong inhibitor of CYP1A2 (IC50 = 0.15 μM) and CYP2C9 (IC50 = 7.4 μM). Based on the AOH depletion assays in the presence of CYP enzymes, CYP1A2 is mainly involved, while CYP2C19 is moderately involved in the CYP-catalyzed biotransformation of the mycotoxin. AOH proved to be a strong inhibitor of each OATP transporter examined (IC50 = 1.9 to 5.4 μM). In addition, both direct and indirect assays suggest the involvement of OATP1B1 in the cellular uptake of the mycotoxin. These findings promote the deeper understanding of certain toxicokinetic interactions of AOH.
Collapse
Affiliation(s)
- Eszter Fliszár-Nyúl
- Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, H-7624 Pécs, Hungary
- Food Biotechnology Research Group, János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, H-7624 Pécs, Hungary
| | - Orsolya Ungvári
- Drug Resistance Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Eötvös Loránd Research Network, Magyar tudósok krt. 2, H-1117 Budapest, Hungary
- Doctoral School of Biology, Institute of Biology, Eötvös Loránd University, Pázmány P. stny. 1/C, H-1117 Budapest, Hungary
| | - Ágnes Dombi
- Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, H-7624 Pécs, Hungary
| | - Csilla Özvegy-Laczka
- Drug Resistance Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Eötvös Loránd Research Network, Magyar tudósok krt. 2, H-1117 Budapest, Hungary
| | - Miklós Poór
- Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, H-7624 Pécs, Hungary
- Food Biotechnology Research Group, János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, H-7624 Pécs, Hungary
- Correspondence:
| |
Collapse
|
4
|
Fan J, Gilmartin K, Octaviano S, Villar F, Remache B, Regan J. Using Human Serum Albumin Binding Affinities as a Proactive Strategy to Affect the Pharmacodynamics and Pharmacokinetics of Preclinical Drug Candidates. ACS Pharmacol Transl Sci 2022; 5:803-810. [PMID: 36110380 PMCID: PMC9469496 DOI: 10.1021/acsptsci.2c00115] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2022] [Indexed: 10/15/2022]
Abstract
We report on a new preclinical drug optimization strategy that measures drug candidates' binding affinity with human serum albumin (HSA) as an assessment of increasing or decreasing serum T1/2. Three common scaffolds were used as drug prototypes. Common polar and nonpolar substituents attached to the scaffolds have been identified as opportunities for increasing or decreasing the HSA binding affinity. This approach of adjusting HSA binding could be proactively established for preclinical drug candidates by appending functionality to sites on the drug scaffold not involved in biological target interactions. This strategy complements other medicinal chemistry efforts to identify longer or shorter human dosing regimens.
Collapse
Affiliation(s)
- Jianwei Fan
- Department of Chemistry and
Biochemistry, Manhattan College, 4513 Manhattan College Parkway, Riverdale, New York 10471, United States
| | - Katherine Gilmartin
- Department of Chemistry and
Biochemistry, Manhattan College, 4513 Manhattan College Parkway, Riverdale, New York 10471, United States
| | - Steven Octaviano
- Department of Chemistry and
Biochemistry, Manhattan College, 4513 Manhattan College Parkway, Riverdale, New York 10471, United States
| | - Francisca Villar
- Department of Chemistry and
Biochemistry, Manhattan College, 4513 Manhattan College Parkway, Riverdale, New York 10471, United States
| | - Brianna Remache
- Department of Chemistry and
Biochemistry, Manhattan College, 4513 Manhattan College Parkway, Riverdale, New York 10471, United States
| | - John Regan
- Department of Chemistry and
Biochemistry, Manhattan College, 4513 Manhattan College Parkway, Riverdale, New York 10471, United States
| |
Collapse
|
5
|
Fliszár-Nyúl E, Faisal Z, Mohos V, Derdák D, Lemli B, Kálai T, Sár C, Zsidó BZ, Hetényi C, Horváth ÁI, Helyes Z, Deme R, Bogdán D, Czompa A, Mátyus P, Poór M. Interaction of SZV 1287, a novel oxime analgesic drug candidate, and its metabolites with serum albumin. J Mol Liq 2021. [DOI: 10.1016/j.molliq.2021.115945] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
|
6
|
Faisal Z, Mohos V, Fliszár-Nyúl E, Valentová K, Káňová K, Lemli B, Kunsági-Máté S, Poór M. Interaction of silymarin components and their sulfate metabolites with human serum albumin and cytochrome P450 (2C9, 2C19, 2D6, and 3A4) enzymes. Biomed Pharmacother 2021; 138:111459. [PMID: 33706132 DOI: 10.1016/j.biopha.2021.111459] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2020] [Revised: 03/01/2021] [Accepted: 03/01/2021] [Indexed: 02/06/2023] Open
Abstract
Silymarin is a mixture of flavonolignans isolated from the fruit of milk thistle (Silybum marianum (L.) Gaertner). Milk thistle extract is the active ingredient of several medications and dietary supplements to treat liver injury/diseases. After the oral administration, flavonolignans are extensively biotransformed, resulting in the formation of sulfate and/or glucuronide metabolites. Previous studies demonstrated that silymarin components form stable complexes with serum albumin and can inhibit certain cytochrome P450 (CYP) enzymes. Nevertheless, in most of these investigations, silybin was tested; while no or only limited information is available regarding other silymarin components and metabolites. In this study, the interactions of five silymarin components (silybin A, silybin B, isosilybin A, silychristin, and 2,3-dehydrosilychristin) and their sulfate metabolites were examined with human serum albumin and CYP (2C9, 2C19, 2D6, and 3A4) enzymes. Our results demonstrate that each compound tested forms stable complexes with albumin, and certain silymarin components/metabolites can inhibit CYP enzymes. Most of the sulfate conjugates were less potent inhibitors of CYP enzymes, but 2,3-dehydrosilychristin-19-O-sulfate showed the strongest inhibitory effect on CYP3A4. Based on these observations, the simultaneous administration of high dose silymarin with medications should be carefully considered, because milk thistle flavonolignans and/or their sulfate metabolites may interfere with drug therapy.
Collapse
Affiliation(s)
- Zelma Faisal
- Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Szigeti út 12, Pécs H-7624, Hungary; János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary.
| | - Violetta Mohos
- Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Szigeti út 12, Pécs H-7624, Hungary; János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary.
| | - Eszter Fliszár-Nyúl
- Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Szigeti út 12, Pécs H-7624, Hungary; János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary.
| | - Kateřina Valentová
- Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, 142 20 Prague, Czech Republic.
| | - Kristýna Káňová
- Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, 142 20 Prague, Czech Republic; University of Chemistry and Technology Prague, Technická 5, 166 28 Prague, Czech Republic.
| | - Beáta Lemli
- János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary; Institute of Organic and Medicinal Chemistry, Medical School, University of Pécs, Szigeti út 12, H-7624 Pécs, Hungary.
| | - Sándor Kunsági-Máté
- János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary; Institute of Organic and Medicinal Chemistry, Medical School, University of Pécs, Szigeti út 12, H-7624 Pécs, Hungary.
| | - Miklós Poór
- Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Szigeti út 12, Pécs H-7624, Hungary; János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary.
| |
Collapse
|
7
|
Fliszár-Nyúl E, Mohos V, Csepregi R, Mladěnka P, Poór M. Inhibitory effects of polyphenols and their colonic metabolites on CYP2D6 enzyme using two different substrates. Biomed Pharmacother 2020; 131:110732. [PMID: 32942157 DOI: 10.1016/j.biopha.2020.110732] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2020] [Revised: 09/03/2020] [Accepted: 09/07/2020] [Indexed: 02/06/2023] Open
Abstract
Polyphenolic compounds (including flavonoids, chalcones, phenolic acids, and furanocoumarins) represent a common part of our diet, but are also the active ingredients of several dietary supplements and/or medications. These compounds undergo extensive metabolism by human biotransformation enzymes and the microbial flora of the colon. CYP2D6 enzyme metabolizes approximately 25% of the drugs, some of which has narrow therapeutic window. Therefore, its inhibition can lead to the development of pharmacokinetic interactions and the disruption of drug therapy. In this study, the inhibitory effects of 17 plant-derived compounds and 19 colonic flavonoid metabolites on CYP2D6 were examined, employing two assays with different test substrates. The O-demethylation of dextromethorphan was tested employing CypExpress 2D6 kit coupled to HPLC analysis; while the O-demethylation of another CYP2D6 specific substrate (AMMC) was investigated in a plate reader assay with BioVision Fluorometric CYP2D6 kit. Interestingly, some compounds (e.g., bergamottin) inhibited both dextromethorphan and AMMC demethylation; however, certain substances proved to be inhibitors only in one of the assays applied. Our results demonstrate that some polyphenols and colonic metabolites are inhibitors of CYP2D6-catalyzed reactions. Nevertheless, the inhibitory effects showed strong substrate dependence.
Collapse
Affiliation(s)
- Eszter Fliszár-Nyúl
- Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Szigeti út 12, H-7624, Pécs, Hungary; Lab-on-a-Chip Research Group, János Szentágothai Research Centre, Ifjúság útja 20, H-7624, Pécs, Hungary.
| | - Violetta Mohos
- Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Szigeti út 12, H-7624, Pécs, Hungary; Lab-on-a-Chip Research Group, János Szentágothai Research Centre, Ifjúság útja 20, H-7624, Pécs, Hungary.
| | - Rita Csepregi
- Lab-on-a-Chip Research Group, János Szentágothai Research Centre, Ifjúság útja 20, H-7624, Pécs, Hungary; Department of Laboratory Medicine, University of Pécs, Medical School, Ifjúság útja 13, H-7624, Pécs, Hungary.
| | - Přemysl Mladěnka
- Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 500 05, Hradec Králové, Czech Republic.
| | - Miklós Poór
- Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Szigeti út 12, H-7624, Pécs, Hungary; Lab-on-a-Chip Research Group, János Szentágothai Research Centre, Ifjúság útja 20, H-7624, Pécs, Hungary.
| |
Collapse
|
8
|
Inhibitory Effects of Quercetin and Its Main Methyl, Sulfate, and Glucuronic Acid Conjugates on Cytochrome P450 Enzymes, and on OATP, BCRP and MRP2 Transporters. Nutrients 2020; 12:nu12082306. [PMID: 32751996 PMCID: PMC7468908 DOI: 10.3390/nu12082306] [Citation(s) in RCA: 42] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2020] [Revised: 07/27/2020] [Accepted: 07/29/2020] [Indexed: 12/11/2022] Open
Abstract
Quercetin is a flavonoid, its glycosides and aglycone are found in significant amounts in several plants and dietary supplements. Because of the high presystemic biotransformation of quercetin, mainly its conjugates appear in circulation. As has been reported in previous studies, quercetin can interact with several proteins of pharmacokinetic importance. However, the interactions of its metabolites with biotransformation enzymes and drug transporters have barely been examined. In this study, the inhibitory effects of quercetin and its most relevant methyl, sulfate, and glucuronide metabolites were tested on cytochrome P450 (CYP) (2C19, 3A4, and 2D6) enzymes as well as on organic anion-transporting polypeptides (OATPs) (OATP1A2, OATP1B1, OATP1B3, and OATP2B1) and ATP (adenosine triphosphate) Binding Cassette (ABC) (BCRP and MRP2) transporters. Quercetin and its metabolites (quercetin-3'-sulfate, quercetin-3-glucuronide, isorhamnetin, and isorhamnetin-3-glucuronide) showed weak inhibitory effects on CYP2C19 and 3A4, while they did not affect CYP2D6 activity. Some of the flavonoids caused weak inhibition of OATP1A2 and MRP2. However, most of the compounds tested proved to be strong inhibitors of OATP1B1, OATP1B3, OATP2B1, and BCRP. Our data demonstrate that not only quercetin but some of its conjugates, can also interact with CYP enzymes and drug transporters. Therefore, high intake of quercetin may interfere with the pharmacokinetics of drugs.
Collapse
|
9
|
Mohos V, Fliszár-Nyúl E, Ungvári O, Bakos É, Kuffa K, Bencsik T, Zsidó BZ, Hetényi C, Telbisz Á, Özvegy-Laczka C, Poór M. Effects of Chrysin and Its Major Conjugated Metabolites Chrysin-7-Sulfate and Chrysin-7-Glucuronide on Cytochrome P450 Enzymes and on OATP, P-gp, BCRP, and MRP2 Transporters. Drug Metab Dispos 2020; 48:1064-1073. [PMID: 32661014 DOI: 10.1124/dmd.120.000085] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2020] [Accepted: 07/01/2020] [Indexed: 12/22/2022] Open
Abstract
Chrysin is an abundant flavonoid in nature, and it is also contained by several dietary supplements. Chrysin is highly biotransformed in the body, during which conjugated metabolites chrysin-7-sulfate and chrysin-7-glucuronide are formed. These conjugates appear at considerably higher concentrations in the circulation than the parent compound. Based on previous studies, chrysin can interact with biotransformation enzymes and transporters; however, the interactions of its metabolites have been barely examined. In this in vitro study, the effects of chrysin, chrysin-7-sulfate, and chrysin-7-glucuronide on cytochrome P450 enzymes (2C9, 2C19, 3A4, and 2D6) as well as on organic anion-transporting polypeptides (OATPs; 1A2, 1B1, 1B3, and 2B1) and ATP binding cassette [P-glycoprotein, multidrug resistance-associated protein 2, and breast cancer resistance protein (BCRP)] transporters were investigated. Our observations revealed that chrysin conjugates are strong inhibitors of certain biotransformation enzymes (e.g., CYP2C9) and transporters (e.g., OATP1B1, OATP1B3, OATP2B1, and BCRP) examined. Therefore, the simultaneous administration of chrysin-containing dietary supplements with medications needs to be carefully considered due to the possible development of pharmacokinetic interactions. SIGNIFICANCE STATEMENT: Chrysin-7-sulfate and chrysin-7-glucuronide are the major metabolites of flavonoid chrysin. In this study, we examined the effects of chrysin and its conjugates on cytochrome P450 enzymes and on organic anion-transporting polypeptides and ATP binding cassette transporters (P-glycoprotein, breast cancer resistance protein, and multidrug resistance-associated protein 2). Our results demonstrate that chrysin and/or its conjugates can significantly inhibit some of these proteins. Since chrysin is also contained by dietary supplements, high intake of chrysin may interrupt the transport and/or the biotransformation of drugs.
Collapse
Affiliation(s)
- Violetta Mohos
- Department of Pharmacology, Faculty of Pharmacy (V.M., E.F.-N., M.P.), János Szentágothai Research Centre (V.M., E.F.-N., M.P.), Department of Pharmacognosy, Faculty of Pharmacy (T.B.), and Department of Pharmacology and Pharmacotherapy, Medical School (B.Z.Z., C.H.), University of Pécs, Pécs, Hungary; and Membrane Protein Research Group (O.U., É.B., C.Ö.-L.) and Biomembrane Research Group (K.K., Á.T.), Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary
| | - Eszter Fliszár-Nyúl
- Department of Pharmacology, Faculty of Pharmacy (V.M., E.F.-N., M.P.), János Szentágothai Research Centre (V.M., E.F.-N., M.P.), Department of Pharmacognosy, Faculty of Pharmacy (T.B.), and Department of Pharmacology and Pharmacotherapy, Medical School (B.Z.Z., C.H.), University of Pécs, Pécs, Hungary; and Membrane Protein Research Group (O.U., É.B., C.Ö.-L.) and Biomembrane Research Group (K.K., Á.T.), Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary
| | - Orsolya Ungvári
- Department of Pharmacology, Faculty of Pharmacy (V.M., E.F.-N., M.P.), János Szentágothai Research Centre (V.M., E.F.-N., M.P.), Department of Pharmacognosy, Faculty of Pharmacy (T.B.), and Department of Pharmacology and Pharmacotherapy, Medical School (B.Z.Z., C.H.), University of Pécs, Pécs, Hungary; and Membrane Protein Research Group (O.U., É.B., C.Ö.-L.) and Biomembrane Research Group (K.K., Á.T.), Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary
| | - Éva Bakos
- Department of Pharmacology, Faculty of Pharmacy (V.M., E.F.-N., M.P.), János Szentágothai Research Centre (V.M., E.F.-N., M.P.), Department of Pharmacognosy, Faculty of Pharmacy (T.B.), and Department of Pharmacology and Pharmacotherapy, Medical School (B.Z.Z., C.H.), University of Pécs, Pécs, Hungary; and Membrane Protein Research Group (O.U., É.B., C.Ö.-L.) and Biomembrane Research Group (K.K., Á.T.), Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary
| | - Katalin Kuffa
- Department of Pharmacology, Faculty of Pharmacy (V.M., E.F.-N., M.P.), János Szentágothai Research Centre (V.M., E.F.-N., M.P.), Department of Pharmacognosy, Faculty of Pharmacy (T.B.), and Department of Pharmacology and Pharmacotherapy, Medical School (B.Z.Z., C.H.), University of Pécs, Pécs, Hungary; and Membrane Protein Research Group (O.U., É.B., C.Ö.-L.) and Biomembrane Research Group (K.K., Á.T.), Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary
| | - Tímea Bencsik
- Department of Pharmacology, Faculty of Pharmacy (V.M., E.F.-N., M.P.), János Szentágothai Research Centre (V.M., E.F.-N., M.P.), Department of Pharmacognosy, Faculty of Pharmacy (T.B.), and Department of Pharmacology and Pharmacotherapy, Medical School (B.Z.Z., C.H.), University of Pécs, Pécs, Hungary; and Membrane Protein Research Group (O.U., É.B., C.Ö.-L.) and Biomembrane Research Group (K.K., Á.T.), Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary
| | - Balázs Zoltán Zsidó
- Department of Pharmacology, Faculty of Pharmacy (V.M., E.F.-N., M.P.), János Szentágothai Research Centre (V.M., E.F.-N., M.P.), Department of Pharmacognosy, Faculty of Pharmacy (T.B.), and Department of Pharmacology and Pharmacotherapy, Medical School (B.Z.Z., C.H.), University of Pécs, Pécs, Hungary; and Membrane Protein Research Group (O.U., É.B., C.Ö.-L.) and Biomembrane Research Group (K.K., Á.T.), Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary
| | - Csaba Hetényi
- Department of Pharmacology, Faculty of Pharmacy (V.M., E.F.-N., M.P.), János Szentágothai Research Centre (V.M., E.F.-N., M.P.), Department of Pharmacognosy, Faculty of Pharmacy (T.B.), and Department of Pharmacology and Pharmacotherapy, Medical School (B.Z.Z., C.H.), University of Pécs, Pécs, Hungary; and Membrane Protein Research Group (O.U., É.B., C.Ö.-L.) and Biomembrane Research Group (K.K., Á.T.), Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary
| | - Ágnes Telbisz
- Department of Pharmacology, Faculty of Pharmacy (V.M., E.F.-N., M.P.), János Szentágothai Research Centre (V.M., E.F.-N., M.P.), Department of Pharmacognosy, Faculty of Pharmacy (T.B.), and Department of Pharmacology and Pharmacotherapy, Medical School (B.Z.Z., C.H.), University of Pécs, Pécs, Hungary; and Membrane Protein Research Group (O.U., É.B., C.Ö.-L.) and Biomembrane Research Group (K.K., Á.T.), Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary
| | - Csilla Özvegy-Laczka
- Department of Pharmacology, Faculty of Pharmacy (V.M., E.F.-N., M.P.), János Szentágothai Research Centre (V.M., E.F.-N., M.P.), Department of Pharmacognosy, Faculty of Pharmacy (T.B.), and Department of Pharmacology and Pharmacotherapy, Medical School (B.Z.Z., C.H.), University of Pécs, Pécs, Hungary; and Membrane Protein Research Group (O.U., É.B., C.Ö.-L.) and Biomembrane Research Group (K.K., Á.T.), Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary
| | - Miklós Poór
- Department of Pharmacology, Faculty of Pharmacy (V.M., E.F.-N., M.P.), János Szentágothai Research Centre (V.M., E.F.-N., M.P.), Department of Pharmacognosy, Faculty of Pharmacy (T.B.), and Department of Pharmacology and Pharmacotherapy, Medical School (B.Z.Z., C.H.), University of Pécs, Pécs, Hungary; and Membrane Protein Research Group (O.U., É.B., C.Ö.-L.) and Biomembrane Research Group (K.K., Á.T.), Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary
| |
Collapse
|
10
|
Faisal Z, Vörös V, Fliszár-Nyúl E, Lemli B, Kunsági-Máté S, Csepregi R, Kőszegi T, Zsila F, Poór M. Probing the Interactions of Ochratoxin B, Ochratoxin C, Patulin, Deoxynivalenol, and T-2 Toxin with Human Serum Albumin. Toxins (Basel) 2020; 12:toxins12060392. [PMID: 32545742 PMCID: PMC7354631 DOI: 10.3390/toxins12060392] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2020] [Revised: 06/08/2020] [Accepted: 06/10/2020] [Indexed: 01/03/2023] Open
Abstract
Ochratoxins, patulin, deoxynivalenol, and T-2 toxin are mycotoxins, and common contaminants in food and drinks. Human serum albumin (HSA) forms complexes with certain mycotoxins. Since HSA can affect the toxicokinetics of bound ligand molecules, the potential interactions of ochratoxin B (OTB), ochratoxin C (OTC), patulin, deoxynivalenol, and T-2 toxin with HSA were examined, employing spectroscopic (fluorescence, UV, and circular dichroism) and ultrafiltration techniques. Furthermore, the influence of albumin on the cytotoxicity of these xenobiotics was also evaluated in cell experiments. Fluorescence studies showed the formation of highly stable OTB–HSA and OTC–HSA complexes. Furthermore, fluorescence quenching and circular dichroism measurements suggest weak or no interaction of patulin, deoxynivalenol, and T-2 toxin with HSA. In ultrafiltration studies, OTB and OTC strongly displaced the Sudlow’s site I ligand warfarin, while other mycotoxins tested did not affect either the albumin binding of warfarin or naproxen. The presence of HSA significantly decreased or even abolished the OTB- and OTC-induced cytotoxicity in cell experiments; however, the toxic impacts of patulin, deoxynivalenol, and T-2 toxin were not affected by HSA. In summary, the complex formation of OTB and OTC with albumin is relevant, whereas the interactions of patulin, deoxynivalenol, and T-2 toxin with HSA may have low toxicological importance.
Collapse
Affiliation(s)
- Zelma Faisal
- Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Szigeti út 12, H-7624 Pécs, Hungary; (Z.F.); (V.V.); (E.F.-N.)
- János Szentágothai Research Centre, Ifjúság útja 20, H-7624 Pécs, Hungary; (B.L.); (S.K.-M.); (R.C.); (T.K.)
| | - Virág Vörös
- Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Szigeti út 12, H-7624 Pécs, Hungary; (Z.F.); (V.V.); (E.F.-N.)
- János Szentágothai Research Centre, Ifjúság útja 20, H-7624 Pécs, Hungary; (B.L.); (S.K.-M.); (R.C.); (T.K.)
| | - Eszter Fliszár-Nyúl
- Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Szigeti út 12, H-7624 Pécs, Hungary; (Z.F.); (V.V.); (E.F.-N.)
- János Szentágothai Research Centre, Ifjúság útja 20, H-7624 Pécs, Hungary; (B.L.); (S.K.-M.); (R.C.); (T.K.)
| | - Beáta Lemli
- János Szentágothai Research Centre, Ifjúság útja 20, H-7624 Pécs, Hungary; (B.L.); (S.K.-M.); (R.C.); (T.K.)
- Institute of Organic and Medicinal Chemistry, Medical School, University of Pécs, Szigeti út 12, H-7624 Pécs, Hungary
| | - Sándor Kunsági-Máté
- János Szentágothai Research Centre, Ifjúság útja 20, H-7624 Pécs, Hungary; (B.L.); (S.K.-M.); (R.C.); (T.K.)
- Institute of Organic and Medicinal Chemistry, Medical School, University of Pécs, Szigeti út 12, H-7624 Pécs, Hungary
| | - Rita Csepregi
- János Szentágothai Research Centre, Ifjúság útja 20, H-7624 Pécs, Hungary; (B.L.); (S.K.-M.); (R.C.); (T.K.)
- Department of Laboratory Medicine, University of Pécs, Medical School, Ifjúság útja 13, H-7624 Pécs, Hungary
| | - Tamás Kőszegi
- János Szentágothai Research Centre, Ifjúság útja 20, H-7624 Pécs, Hungary; (B.L.); (S.K.-M.); (R.C.); (T.K.)
- Department of Laboratory Medicine, University of Pécs, Medical School, Ifjúság útja 13, H-7624 Pécs, Hungary
| | - Ferenc Zsila
- Institute of Materials and Environmental Chemistry, Research Centre for Natural Sciences, Magyar Tudósok krt. 2, H-1117 Budapest, Hungary;
| | - Miklós Poór
- Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Szigeti út 12, H-7624 Pécs, Hungary; (Z.F.); (V.V.); (E.F.-N.)
- János Szentágothai Research Centre, Ifjúság útja 20, H-7624 Pécs, Hungary; (B.L.); (S.K.-M.); (R.C.); (T.K.)
- Correspondence: ; Tel.: +36-536-000 (ext. 35052)
| |
Collapse
|
11
|
Mohos V, Fliszár-Nyúl E, Lemli B, Zsidó BZ, Hetényi C, Mladěnka P, Horký P, Pour M, Poór M. Testing the Pharmacokinetic Interactions of 24 Colonic Flavonoid Metabolites with Human Serum Albumin and Cytochrome P450 Enzymes. Biomolecules 2020; 10:E409. [PMID: 32155912 PMCID: PMC7175153 DOI: 10.3390/biom10030409] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2020] [Revised: 03/03/2020] [Accepted: 03/03/2020] [Indexed: 12/21/2022] Open
Abstract
Flavonoids are abundant polyphenols in nature. They are extensively biotransformed in enterocytes and hepatocytes, where conjugated (methyl, sulfate, and glucuronide) metabolites are formed. However, bacterial microflora in the human intestines also metabolize flavonoids, resulting in the production of smaller phenolic fragments (e.g., hydroxybenzoic, hydroxyacetic and hydroxycinnamic acids, and hydroxybenzenes). Despite the fact that several colonic metabolites appear in the circulation at high concentrations, we have only limited information regarding their pharmacodynamic effects and pharmacokinetic interactions. Therefore, in this in vitro study, we investigated the interactions of 24 microbial flavonoid metabolites with human serum albumin and cytochrome P450 (CYP2C9, 2C19, and 3A4) enzymes. Our results demonstrated that some metabolites (e.g., 2,4-dihydroxyacetophenone, pyrogallol, O-desmethylangolensin, and 2-hydroxy-4-methoxybenzoic acid) form stable complexes with albumin. However, the compounds tested did not considerably displace Site I and II marker drugs from albumin. All CYP isoforms examined were significantly inhibited by O-desmethylangolensin; nevertheless, only its effect on CYP2C9 seems to be relevant. Furthermore, resorcinol and phloroglucinol showed strong inhibitory effects on CYP3A4. Our results demonstrate that, besides flavonoid aglycones and their conjugated derivatives, some colonic metabolites are also able to interact with proteins involved in the pharmacokinetics of drugs.
Collapse
Affiliation(s)
- Violetta Mohos
- Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Szigeti út 12, H-7624 Pécs, Hungary; (V.M.); (E.F.-N.)
- János Szentágothai Research Center, University of Pécs, Ifjúság útja 20, H-7624 Pécs, Hungary; (B.L.)
| | - Eszter Fliszár-Nyúl
- Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Szigeti út 12, H-7624 Pécs, Hungary; (V.M.); (E.F.-N.)
- János Szentágothai Research Center, University of Pécs, Ifjúság útja 20, H-7624 Pécs, Hungary; (B.L.)
| | - Beáta Lemli
- János Szentágothai Research Center, University of Pécs, Ifjúság útja 20, H-7624 Pécs, Hungary; (B.L.)
- Institute of Organic and Medicinal Chemistry, Medical School, University of Pécs, Szigeti út 12, H-7624 Pécs, Hungary
| | - Balázs Zoltán Zsidó
- Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Szigeti út 12, H-7624 Pécs, Hungary; (B.Z.Z.); (C.H.)
| | - Csaba Hetényi
- Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Szigeti út 12, H-7624 Pécs, Hungary; (B.Z.Z.); (C.H.)
| | - Přemysl Mladěnka
- Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic; (P.M.)
| | - Pavel Horký
- Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic; (P.H.)
- Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Králové, Charles University, Zborovská 2089, 500 05 Hradec Králové, Czech Republic
| | - Milan Pour
- Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic; (P.H.)
| | - Miklós Poór
- Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Szigeti út 12, H-7624 Pécs, Hungary; (V.M.); (E.F.-N.)
- János Szentágothai Research Center, University of Pécs, Ifjúság útja 20, H-7624 Pécs, Hungary; (B.L.)
| |
Collapse
|
12
|
Zsidó BZ, Balog M, Erős N, Poór M, Mohos V, Fliszár-Nyúl E, Hetényi C, Nagane M, Hideg K, Kálai T, Bognár B. Synthesis of Spin-Labelled Bergamottin: A Potent CYP3A4 Inhibitor with Antiproliferative Activity. Int J Mol Sci 2020; 21:ijms21020508. [PMID: 31941150 PMCID: PMC7013880 DOI: 10.3390/ijms21020508] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2019] [Revised: 01/09/2020] [Accepted: 01/10/2020] [Indexed: 12/13/2022] Open
Abstract
Bergamottin (BM, 1), a component of grapefruit juice, acts as an inhibitor of some isoforms of the cytochrome P450 (CYP) enzyme, particularly CYP3A4. Herein, a new bergamottin containing a nitroxide moiety (SL-bergamottin, SL-BM, 10) was synthesized; chemically characterized, evaluated as a potential inhibitor of the CYP2C19, CYP3A4, and CYP2C9 enzymes; and compared to BM and known inhibitors such as ketoconazole (KET) (3A4), warfarin (WAR) (2C9), and ticlopidine (TIC) (2C19). The antitumor activity of the new SL-bergamottin was also investigated. Among the compounds studied, BM showed the strongest inhibition of the CYP2C9 and 2C19 enzymes. SL-BM is a more potent inhibitor of CYP3A4 than the parent compound; this finding was also supported by docking studies, suggesting that the binding positions of BM and SL-BM to the active site of CYP3A4 are very similar, but that SL-BM had a better ∆Gbind value than that of BM. The nitroxide moiety markedly increased the antitumor activity of BM toward HeLa cells and marginally increased its toxicity toward a normal cell line. In conclusion, modification of the geranyl sidechain of BM can result in new CYP3A4 enzyme inhibitors with strong antitumor effects.
Collapse
Affiliation(s)
- Balázs Zoltán Zsidó
- Department of Pharmacology and Pharmacotherapy, University of Pécs, Medical School, Szigeti út 12, H-7624 Pécs, Hungary (C.H.)
| | - Mária Balog
- Institute of Organic and Medicinal Chemistry, University of Pécs, Medical School, Honvéd utca 1, H-7624 Pécs, Hungary; (M.B.); (N.E.); (K.H.); (T.K.)
| | - Nikolett Erős
- Institute of Organic and Medicinal Chemistry, University of Pécs, Medical School, Honvéd utca 1, H-7624 Pécs, Hungary; (M.B.); (N.E.); (K.H.); (T.K.)
| | - Miklós Poór
- Department of Pharmacology, University of Pécs, Faculty of Pharmacy, Szigeti út 12, H-7624 Pécs, Hungary; (M.P.); (V.M.); (E.F.-N.)
- János Szentágothai Research Center, University of Pécs, Ifjúság útja 20, H-7624 Pécs, Hungary
| | - Violetta Mohos
- Department of Pharmacology, University of Pécs, Faculty of Pharmacy, Szigeti út 12, H-7624 Pécs, Hungary; (M.P.); (V.M.); (E.F.-N.)
- János Szentágothai Research Center, University of Pécs, Ifjúság útja 20, H-7624 Pécs, Hungary
| | - Eszter Fliszár-Nyúl
- Department of Pharmacology, University of Pécs, Faculty of Pharmacy, Szigeti út 12, H-7624 Pécs, Hungary; (M.P.); (V.M.); (E.F.-N.)
- János Szentágothai Research Center, University of Pécs, Ifjúság útja 20, H-7624 Pécs, Hungary
| | - Csaba Hetényi
- Department of Pharmacology and Pharmacotherapy, University of Pécs, Medical School, Szigeti út 12, H-7624 Pécs, Hungary (C.H.)
| | - Masaki Nagane
- Department of Biochemistry, School of Veterinary Medicine, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara, Kanagawa 252-5201, Japan;
| | - Kálmán Hideg
- Institute of Organic and Medicinal Chemistry, University of Pécs, Medical School, Honvéd utca 1, H-7624 Pécs, Hungary; (M.B.); (N.E.); (K.H.); (T.K.)
| | - Tamás Kálai
- Institute of Organic and Medicinal Chemistry, University of Pécs, Medical School, Honvéd utca 1, H-7624 Pécs, Hungary; (M.B.); (N.E.); (K.H.); (T.K.)
- János Szentágothai Research Center, University of Pécs, Ifjúság útja 20, H-7624 Pécs, Hungary
| | - Balázs Bognár
- Institute of Organic and Medicinal Chemistry, University of Pécs, Medical School, Honvéd utca 1, H-7624 Pécs, Hungary; (M.B.); (N.E.); (K.H.); (T.K.)
- Correspondence: or ; Tel.: +36-536-220
| |
Collapse
|